AstraZeneca PLC
LSE:AZN 주식 보고서
AstraZeneca 과거 수익 실적 AstraZeneca은 연평균 26.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 감소했으며, 연간 5.2%였습니다. 매출은 연평균 16.6%의 비율로 증가했습니다. AstraZeneca의 자기자본이익률은 16.3%이고 순이익률은 13.1%입니다.
주요 정보 Pharmaceuticals 산업 성장 14.1% 매출 성장률 16.6% 자기자본 수익률 16.3% 순이익 13.1% 다음 실적 업데이트 06 Feb 2025
최근 과거 실적 업데이트
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 26
모든 업데이트 표시 Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps Nov 08
Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Nov 02
Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union Oct 21
AstraZeneca PLC's (LON:AZN) Price In Tune With Earnings Oct 19 AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial Oct 08
AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial Oct 07
Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma Oct 04
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma Oct 03
Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US Oct 02
Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy Oct 01
Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer Sep 26
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer Sep 24
AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US Sep 21
AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis Sep 18
AstraZeneca Announces Positive Results from the Niagara Phase III Trial Sep 16
Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases Sep 14
Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024 Sep 09
Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery Aug 16
Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US Aug 15
Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial Jul 30
AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776 Jul 30 Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial Jul 30
First half dividend of UK£0.78 announced Jul 28 FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results Jul 27
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 26 Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis Jul 23
AstraZeneca 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역 LSE:AZN 수익, 비용 및 수입 (USD Millions ) 날짜 수익 수익 G+A 비용 R&D 비용 30 Jun 24 49,133 6,440 18,268 10,955 31 Mar 24 47,611 6,331 18,365 10,662 31 Dec 23 45,811 5,955 18,025 10,299 30 Sep 23 44,994 5,896 17,769 9,928 30 Jun 23 44,485 6,163 17,732 9,782 31 Mar 23 43,840 4,705 17,425 9,642 31 Dec 22 44,351 3,288 17,422 9,529 30 Sep 22 45,155 2,040 17,425 9,134 30 Jun 22 44,038 -1,253 17,232 9,184 31 Mar 22 41,487 -1,063 15,623 8,535 31 Dec 21 37,417 112 14,673 8,049 30 Sep 21 32,816 1,471 13,651 7,831 30 Jun 21 29,528 3,771 12,270 6,888 31 Mar 21 27,583 3,977 11,808 6,448 31 Dec 20 26,617 3,196 11,586 5,901 30 Sep 20 25,871 2,497 10,909 5,653 30 Jun 20 25,699 2,148 11,367 5,504 31 Mar 20 25,247 1,522 11,652 5,471 31 Dec 19 24,384 1,335 11,438 5,349 30 Sep 19 24,137 2,056 12,134 5,442 30 Jun 19 23,071 2,188 11,317 5,338 31 Mar 19 22,403 2,408 10,880 5,313 31 Dec 18 22,090 2,155 10,822 5,299 30 Sep 18 21,450 2,422 9,850 5,251 30 Jun 18 22,342 2,677 9,885 5,378 31 Mar 18 22,238 2,804 9,625 5,358 31 Dec 17 22,465 3,001 9,406 5,455 30 Sep 17 22,273 3,542 9,251 5,507 30 Jun 17 21,740 3,870 9,049 5,501 31 Mar 17 22,292 3,390 9,645 5,586 31 Dec 16 23,002 3,499 9,743 5,679 30 Sep 16 23,816 2,465 10,464 5,790 30 Jun 16 24,062 2,221 10,784 5,800 31 Mar 16 24,766 2,921 10,796 5,808 31 Dec 15 24,708 2,825 11,024 5,660 30 Sep 15 25,025 1,696 11,796 5,392 30 Jun 15 25,689 1,180 12,255 5,361 31 Mar 15 26,144 1,279 12,280 5,180 31 Dec 14 26,547 1,233 12,219 5,001 30 Sep 14 26,675 1,030 11,601 4,975 30 Jun 14 26,316 2,022 10,977 4,438 31 Mar 14 25,786 2,049 10,476 4,428 31 Dec 13 25,806 2,556 10,057 4,281
양질의 수익: AZN 에는 $3.3B 큰 일회성 손실이 있습니다. $3.3B 은 지난 12개월 간의 재무 결과에 30th June, 2024 까지 영향을 미쳤습니다.
이익 마진 증가: AZN 의 현재 순이익 이익률 (13.1%) 작년보다 낮습니다 (13.9%).
과거 수익 성장 분석
수익추이: AZN 의 수익은 지난 5년 동안 매년 26.8% 씩 크게 증가했습니다.
성장 가속화: 지난 1년간 AZN 의 수익 증가율( 4.5% )은 5년 평균( 26.8% 보다 낮습니다. 년도).
수익 대 산업: 지난 1년간 AZN 수익 증가율( 4.5% )은 Pharmaceuticals 업계 4.5% 초과했습니다.
자기자본 수익률
높은 ROE: AZN 의 자본 수익률 ( 16.3% )은 낮음 으로 간주됩니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
